TruthArchive.ai - Related Video Feed

Dr. Pretorius and a colleague discuss unusual clotting observed after COVID-19 vaccination, including embalmers reporting back pressure when introducing embalming fluid and the extraction of very long, congealed clots—six inches to several feet—as well as patients with long brachial clots. They note thousands of clotting reports in VAERS across all vaccine types, describing these clots as not normal. Some clots cause major emboli affecting circulation to the lungs, detected by scans and perfusion studies, while others are microclots with a branching pattern visible in imaging. A clinician also shared a photo of a clot with a complete branching pattern into medium and smaller vessels. Dr. Pretorius’ work is cited to explain the mechanism: spike protein can induce immediate clumping of proteins in platelet-poor plasma in the absence of platelets, a highly unusual clotting pathway not relying on the classical coagulation cascade. This is described as a proteinaceous, pseudo-amyloid–like clot. The spike protein is reported to circulate after vaccination, with studies in the Journal of Immunology showing spikes in circulation and exosomes up to four months after shots. Long-haul COVID data (Patterson’s study) reportedly shows S1 protein present in nonclassical monocytes in blood, suggesting persistence of spike protein, whether from infection or the vaccine, which can induce clotting pathways on its own. Dr. Pretorius discusses observations of upregulation of intercellular adhesion molecules (ICAMs) on leukocytes within clots, causing white blood cells to adhere in addition to fibrin, contributing to difficulty in dissolving these clots. Concerning treatment and detection, the speakers describe depletion of plasminogen, reducing the body’s ability to break down clots, and note that standard anticoagulants are less effective against these clots, which are described as amyloid-like and atypical. They emphasize that these are not the classical clotting pathways involving platelet activation and typical thrombin–fibrin cascades. They contrast this with expectations of standard clotting mechanisms and reference the unusual, non-classical pathway highlighted by Pretorius. The discussion also mentions the idea that spike protein in circulation can drive clotting without the usual platelet activation, and that some patients have continued to experience spike-related effects long after vaccination. They assert that vaccines were developed targeting the original Wuhan strain and may not cover Omicron; they suggest the shot’s risk-benefit balance is unfavorable given ongoing clotting, immune suppression, and cancer-inducing pathways, and they claim data indicate those who receive two or three shots may acquire Omicron at a higher rate than those unvaccinated. They conclude that the shot is expired for a virus that is no longer circulating in its original form and argue that vaccination induces dangerous pathologic processes with no protective benefit.

The CDC in the US has found numerous issues related to vaccines. There are high rates of miscarriage, severe prematurity, and birth defects in children. The CDC comments on gynecological side effects, specifically blood clots in the placenta. Babies are being born with clots in their placenta, which may be linked to the vaccine's effects. Placenta analysis often reveals thrombosis, and healthcare professionals have reported finding small clots regularly. Further studies and analysis are needed to fully understand this issue.

Genes from injected vaccines enter bloodstream and cells lining vessel walls, producing spikes. Lymphocytes attack these cells, leading to clot formation. Antibodies appear after 3-4 weeks, attacking vessel wall cells. Vaccination creates unique situation with unknown outcome. Advises against second or any future shots due to potential dangers revealed in recent publications. Calls for discussion and action to address potential risks.

The symposium covers the potential safety and threat of “replicating” vaccines, especially LepriCon (leprecon) vaccines, in the context of Covid-19 vaccines and genome‑editing concepts. The speakers present a chain of claims and concerns, some drawing on reports and others presenting theories about how these next‑generation vaccines could behave in humans and populations. Key points and claims presented - Emerging mechanisms and risks: The panel notes that blood vessel inflammation and thrombosis mechanisms are increasingly observed, including in vaccine contexts, with examples from individuals who needed limb amputation and others who developed severe vascular events after vaccination. One case involved a 70‑year‑old man who, after a third dose, developed embolic events necessitating shoulder joint surgery, and another where a 60‑year‑old man developed acute limb ischemia and died; both are presented as suggesting a serious vascular mechanism linked to vaccination, though causal connections are not established. - Replicating/vector vaccines and their concerns:荒川博士 and others discuss LepiCon vaccines as vaccines that replicate inside the body. The concept involves “replicating viral vectors” where the genome can mutate and evolve during replication. The green‑highlighted segment in a slide (the antigen gene) plus a blue/orange segment (replicating gene cassette) is used to describe how LepriCon vaccines are designed to carry viral genes and replicate, with the assertion that replication, mutation, and recombination can occur, potentially generating new variants inside the host. - Differences from conventional vaccines: The discussion contrasts LepriCon vaccines with standard mRNA vaccines. In conventional mRNA vaccines, messenger RNA is delivered and translated into antigen proteins, then degraded; in LepriCon vaccines, replicating RNA/DNA can persist and continue producing antigen, with mutation and recombination possible. The panel emphasizes that LepriCon vaccines use replicating/copying mechanisms and that the genetic material can be copied in ways that differ from natural human biology, potentially creating unpredictable variants. - Central dogma and exceptions: The speakers reference the central dogma (DNA → RNA → protein) but note exceptions in viruses, including RNA viruses that can reverse‑transcribe to DNA (retroviruses) and RNA viruses that replicate RNA directly. They discuss how LepriCon vaccines would rely on replicative processes that do not follow the usual linear flow and why this could complicate predictions about safety and behavior in humans. - Potential for unintended spread and environmental impact: A major concern raised is that self‑replicating vectors could spread beyond the vaccinated individual, via exosomes or other intercellular transport, creating secondary infections or non‑target spread. Exosomes could ferry replicating genetic material, raising fears of new infection chains or “outbreaks” stemming from the vaccine itself, and even suggesting the possibility of vaccination‑induced spread akin to an attenuated or modified pathogen. - Safety signals and immunology concerns: The discussion touches on immune system risks, including immune dysregulation, autoimmune phenomena, and unexpected inflammatory responses. IGG4‑related disease is highlighted as a potential adverse outcome post‑vaccination, with descriptions of glandular and systemic involvement and the idea that high IGG4 levels could have immunosuppressive effects that alter responses to infection or vaccination. The panel notes observed increases in certain immunoglobulin subclasses after multiple LepriCon doses and discusses the possibility of immune tolerance or enhanced immune responses that could be harmful. - Historical and theoretical context: References are made to past epidemics and speculative pandemics caused by misused or dangerous vaccine platforms, drawing on central molecular biology concepts and historical anecdotes about how vaccines can be designed and misused. The discussion frames LepriCon vaccines as a high‑risk platform that could, in theory, generate recombinants, escape mutations, or cause unintended immune and inflammatory consequences. - Clinical and regulatory implications: The speakers call for caution, arguing that more evidence is needed before approving or widespread use of LepriCon vaccines. They emphasize the need for long‑term observation and transparent communication about risks, and criticize the potential for insufficient understanding among healthcare workers and the public. They also urge that any future vaccine development should consider the possibility of genome editing, recombination, and exosome‑mediated spread, and stress the importance of not underestimating possible adverse effects. - Real‑world observations and skepticism about hype: Several speakers underscore that the danger is not merely hypothetical; there are reports of adverse events, including stroke‑like conditions, inflammatory diseases, and immune dysregulation in vaccinated individuals. They stress that the evolution and mutation of replicating vaccines could outpace current surveillance methods, and that “information manipulation” or lack of transparent reporting could mislead the public about risks. - Final reflections and call to action: The concluding messages advocate recognizing the potential failures of messenger RNA vaccines and acknowledging that both conventional and replicating platforms may carry risks. The speakers urge ongoing critical analysis, cautious progression, and robust verification of claims through transparent, independent investigation. They close with thanks to the organizers and a hope that the discussion may contribute to broader public awareness and informed decision‑making. Notable emphasis and unique considerations - The core concern centers on LepriCon vaccines’ replication, mutation, and potential to spread beyond the vaccinated person; exosome transport and genomic/cellular integration are highlighted as mechanisms that could generate new risks not present with non‑replicating vaccines. - The discussion stresses that IGG4 responses could become alarmingly high after certain doses, potentially leading to immunosuppressive effects or autoimmune phenomena, and presents IGG4‑related disease as a potential complication to monitor. - The speakers insist that safety and transparency are paramount, and that misinformation or optimistic narratives about rapid vaccine development could lead to harm if new platforms are adopted without comprehensive evaluation. Overall, the symposium foregrounds cautious scrutiny of replicating vaccine platforms, frames potential biological and regulatory risks, and calls for careful, evidence‑based assessment before broader deployment.

There have been reports of blood clots in patients who have received the vaccine. These clots have been found in living patients and have also been observed in post-mortem examinations. The clots are made up of fibrous material and unusual combinations of proteins that make them difficult for the body to dissolve. However, it is important to note that not everyone who receives the vaccine will experience these clots. One possible solution is the use of an enzyme called Nattokinase, derived from fermented soy, which has been shown to break down fibrin and dissolve clots. Further research is needed to fully understand and address this issue.

We invited the staff of the Giovannini studio to discuss their study on the blood of over a thousand people, including those who were inoculated and those who were not. They found that the blood of inoculated individuals showed alterations in shape and arrangement of red blood cells when observed under dark field microscopy. In a normal blood sample, the red blood cells are spherical and well-oxygenated, with no foreign bodies present. However, in the blood of inoculated individuals, they observed the presence of nanotube-shaped inclusions that attracted red blood cells, leading to potential circulatory issues. This phenomenon, known as impelamento, can have thrombogenic effects. This occurs specifically in the blood of inoculated individuals.

People tested at Quest have an upper antibody limit of 25,000. Unvaccinated individuals typically test under 1,000. Vaccinated individuals often test over 25,000, averaging ten times higher than the unvaccinated, even four years post-vaccination. These high antibody levels are alarming, suggesting persistent spike protein presence and potential health issues. COVID is no longer a major illness concern, but elevated antibody levels remain a concern.

US life insurance companies have reported a significant increase in all-cause deaths among 18 to 49-year-olds, along with certain medical conditions such as miscarriages and blood clots. Concerns have been raised about the unique changes in blood observed in individuals who have died, including those who were vaccinated. The Malthusian theory, which suggests that there are too many people using up resources, is discussed as a potential explanation for the increase in deaths. The video also highlights the experiences of embalmers who have noticed unusual clots in bodies, as well as the impact on pregnancy and stillbirth rates. The speaker emphasizes the need for open discussion and investigation into the safety and efficacy of vaccines.

Pregnant women who have received the COVID-19 vaccine are experiencing rare but serious complications, including increased risk of blood clots. The vaccine can make blood clotting stronger, which poses a danger to both the mother and the baby. This can lead to difficulties in blood flow to the baby and other dangerous situations. It is important to note that the COVID-19 vaccine is still being researched and its safety is not guaranteed. Caution is advised when considering vaccination.

In the past, we did not see blood clotting like this before COVID-19 vaccinations. A marathon runner had severe issues walking after vaccination, requiring treatments like plasma freezes. Clot formations indicate ongoing damage to blood vessel linings, leading to clot formation. Multiple vaccinated individuals experience circulation problems in cold temperatures, with symptoms improving in warmer weather.

The data indicates that vaccinations have led to serious health issues, including blood clots, strokes, and amputations. A simple d-dimer test can reveal the presence of blood clots, yet the government has not mandated this test for vaccinated individuals. Studies by two cardiologists found that over 80% of vaccinated patients had elevated d-dimer levels, suggesting microemboli, which can cause gradual organ failure and increase the risk of severe thrombosis, particularly in the brain. Cases of thrombosis in young people are rising, likely due to microemboli and the spike protein from the vaccine affecting blood vessel walls. This connection has been established through clinical observations.

Reports from the DMED database in 2021, after the vaccine rollout, show alarming increases in several conditions. Myocarditis reports increased 2800%. Cancers of various types increased 300 to 900%. Infertility in both genders increased 500%. Miscarriages increased 300%. Neurological disorders increased 1000%. Demyelinating disorders increased 500%. MS increased 600%. Guillain Barre syndrome saw a 500% increase. HIV increased 500%. Pulmonary embolism increased 400%. These are presented as some of the most alarming findings in the DMED database.

There are real cases of blood clots in patients who have received the vaccine. These clots are thick and fibrous and can be seen in living patients. A tube of blood from a patient with cold-induced finger pain showed the same fibrils as the clots. The body has difficulty breaking down the material in the clots, including amyloid. Autopsies were discouraged early on, so these clots may not have been discovered. Morticians have noticed unusual back pressure when preserving bodies. The clots contain collected proteins and unusual combinations that are hard to dissolve. Nattokinase, an enzyme found in fermented soy, can break down fibrin and may be helpful in dissolving clots.

The spike protein, according to research in South Africa, induces fibrin from fibrinogen, forming the backbone of clotting in a way not previously seen. Unlike normal fibrin clots that are easily broken down, clots formed from COVID or the spike protein from the vaccine are difficult to break down, causing issues for many people. A cardiologist stated that in their decades of practice, they have never treated as many blood clots as in the last five years. These blood clots occur after the virus infection and the vaccine because the spike protein causes blood clots. Therefore, it is reckless to continue vaccinating people and loading the body with spike protein, causing more blood clots. According to a paper in Cell (July 2021), the nucleoprotein, not the spike protein, supplied broad and durable immunity for the prevention of infection. The speaker questions why the vaccine wasn't changed to target the nucleoprotein once this information came to light.

I recently conducted a survey of embalmers, and 73% of the 269 respondents reported finding white fibrous clots in corpses during 2023. These clots, which consist of fibrin, platelets, and amyloid-like material, are suspected to be a contributing factor in strokes and heart attacks. Embalmers are finding these clots are making it necessary to use multiple injection sites, lengthening the embalming process. While similar clots were observed in 2020, during the initial COVID outbreak, their prevalence exploded with the introduction of vaccines in 2021. The spike protein from the virus and vaccines may be responsible for the formation of these clots. Additionally, embalmers are reporting increases in microclotting and traditional grape jelly clots. One theory suggests "frame shifting," where ribosomes misread the modified RNA code from vaccines, creating aberrant proteins that form amyloid material. I can be contacted at thomashaveland@sbcglobal.net.

I found many clinicians dismissing the importance of asking about vaccination status when treating patients with blood clots. Despite frustrations, I continue to see cases where this information is overlooked. Collaborating with physicians in Birmingham, we witnessed an increase in severe cases, including young individuals with atrial fibrillation. I made the decision to prioritize patient care over job security, treating over 2,000 patients, including those with vaccine injuries.

White fibrous clots found in the living and dead recipients of mRNA vaccines are being ignored, but research reveals their composition and cause. The spike protein mutates fibrin into jagged, misfolded, insoluble amyloid, similar to prionic infections. Microclots form and align into large white clots, initiated by spike protein fragments like spike 601. Prolene, a "kinker protein" added to the spike protein, causes misfolding, with proline being prevalent in the clots. A 2021 paper showed the SARS CoV-2 spike induces abnormal blood clots due to the fibrinogen beta chain. Plasma exposed to the spike protein is imbalanced, with the fibrinogen beta chain being dominant. These clots contain four times the normal amount of phosphorus, released from lipid nanoparticles. Similar clots in 1988 were caused by sulfur-based heparin, which was resolved by reducing sulfur content. A 2017 paper showed altered phosphorus levels cause cancer. Thomas Havilland, who shares this information, is being ignored by mainstream and alternative media. Undertakers are seeing massive white fibrous clots at record levels.

They said stroke only happened to the old, but hospitals started seeing something new. Healthy people suddenly clotting. Coincidence? Maybe. But after 2021, studies began tracing small patterns, inflammation, platelets, micro clots weeks after certain shots. Most never notice but for a few, the immune system hits too hard. The same spike that's meant to protect starts sticking to vessel walls. Breath thickens, flow slows, boom. Ischemia. Doctors call vaccine induced immune thrombotic events. Rare, yes, imagined, no. Its indolentacid and negem. The question isn't if it happens but why somebody's break the code. Genetics, guts, toxins, maybe all three. Because when the system builds to defend starts to misfire the result isn't protection, it's a stroke.

US life insurance companies have reported a significant increase in all-cause deaths among 18 to 49-year-olds, along with an increase in certain medical diagnoses. Some individuals suspect that the COVID-19 vaccine may be the cause of these anomalies, as they have observed unique changes in the blood of those who have died. They believe that the vaccines are part of a larger agenda to depopulate and control the world's population. Medical professionals have also noticed an increase in stillbirths, miscarriages, and other adverse effects in pregnant women who have been vaccinated. However, there is a lack of official investigation and acknowledgment of these concerns.

After the vaccine rollout in 2021, reports from the DMED showed significant increases in health issues: myocarditis by 200%, various cancers by 300-900%, infertility by 500% for both genders, miscarriages by 300%, neurological disorders by 1000%, demyelinating disorders by 500%, MS by 600%, Guillain Barre syndrome by 500%, HIV by 500%, and pulmonary embolisms by 400%. These are just a few of the concerning findings in the database.

The speaker has been sequencing clots and found real human DNA, showing a signature of neutrophil extracellular traps, a reaction occurring in sepsis when the immune system clots around foreign entities. This process takes free-circulating DNA into clotting structures, leaving a specific signature. Sequencing reveals patient genome sequences that might predispose them to clotting. While billions received shots, not everyone clotted, suggesting a subset has a bad reaction. Genetic predispositions in the clotting cascade may increase risk. Initial analysis of two clots shows high-impact variants in genes involved in fibrin formation and clotting. Kevin McCarran's work demonstrates some clots bind thiophlavin, a marker for amyloid, suggesting a potential amyloidosis issue. Pathology needs careful examination as it may underlie clotting problems. This information is being suppressed, but citations are provided for reference.

Residual effects from one or two COVID shots can include late blood clots and cardiac arrests years later. The mRNA and spike protein from the shots can linger in the body, causing various health issues like heart and brain damage, blood clots, and immunologic problems. A spike detox program is recommended to address these concerns.

The panel discusses replication (replicon) vaccines and their potential dangers, focusing on how they differ from conventional messenger RNA (mRNA) vaccines and what new risks might emerge as this technology develops. Key points and concerns raised - Replicon vaccines concept and fundamental differences - Replicon vaccines use replication-capable genetic material, so the embedded genetic information not only makes antigen proteins but also multiplies inside the cell. They are described as having both constitutive function (the ability to make proteins) and, crucially, the capacity to replicate, which distinguishes them from traditional, non-replicating mRNA vaccines. - It is explained that replication introduces additional mutation and recombination opportunities, because the RNA genome is copied more than once, and the process can produce variants that differ from the original design. - Central dogma exceptions and viral biology - The speakers explain that while the central dogma (DNA → RNA → protein) generally governs biology, some viruses violate this, with RNA viruses that replicate via RNA-dependent replication and even some reverse-transcribing retroviruses that convert RNA to DNA and integrate into genomes. This context is used to frame why replicon vaccines could behave unpredictably. - Potential risks of replication and spread - A core concern is that the replicon approach might allow the vaccine genome to spread beyond the initial target cells, potentially reaching other cells and tissues, or even spreading to other people via exosomes or other means. Exosomes can transport DNA, RNA, and proteins between cells; thus, the replicon genome could in theory be disseminated. - The possibility of homologous or heterologous recombination between replicon genomes and wild-type viruses could yield new variants. The panel emphasizes the difficulty of controlling such recombination in a living system. - Specific material and design considerations - The use of viral components like spike protein genes in replicon vaccines raises concerns about how these proteins might mutate or recombine during replication, potentially altering antigen presentation or safety. - A concern is raised about the lack of repair mechanisms in RNA replication (as opposed to DNA replication), which could make error rates higher and lead to unpredictable changes. - The panel notes that current replicon vaccine designs (including those using alphavirus backbones) inherently carry high mutation and recombination risk, and that the replicating systems may encounter unpredictable evolutionary dynamics inside the human body. - Safety signals and clinical anecdotes - The speakers cite cases of adverse events temporally associated with vaccines, including vascular inflammation and thrombosis, stroke-like events, and myocarditis, to illustrate that immune responses to vaccines can be complex and occasionally severe. They emphasize that such observations do not establish causality, but argue they warrant careful scrutiny. - There are references to cases of acute vascular and neural complications following repeated vaccination, and to broader immune dysregulation phenomena, including IGG4-related disease and immune dysregulation syndromes that can involve multiple organs. - One example concerns a patient who developed sudden limb problems after the third dose, requiring surgery; another describes myocardial involvement after multiple doses and subsequent inflammatory sequelae. - DNA contamination and analytical findings - Kevin McKernan’s analysis of certain Japanese CoronaVac vaccines is cited: both DNA contamination and the presence of SV40 promoter elements were detected in some vaccine lots, with DNA amounts exceeding some regulatory benchmarks in at least one case. The concern is that DNA contamination, or the presence of promoter sequences, could influence integration or expression in unintended ways. - It is noted that vaccines using lipid nanoparticles can potentially deliver nucleic acids into cells; in the presence of exons or promoter sequences, there could be unintended cellular uptake and expression. - Implications for public health and policy - The panel underscores the need for caution, thorough investigation, and long-term observation of any replication-based vaccine platform before broad deployment. There is a call to evaluate risks, monitor long-term outcomes, and consider the possibility that replication-competent constructs could drive unforeseen evolutionary dynamics within hosts or communities. - There is contention about how information is communicated to the public, with particular emphasis on avoiding misinformation while ensuring that scientific uncertainties are transparently discussed. - Broader scientific context and forward-looking stance - The speakers discuss how the field’s approach to gene-based vaccines is evolving rapidly, and they stress that the compatibility of replicon systems with human biology is not yet fully understood. - They frame their discussion as not merely about current vaccines but about the trajectory of vaccine platforms: if replication-based or self-dispersing systems prove too risky or unpredictable, the prudent path might be to favor conventional, non-replicating strategies until safety, efficacy, and containment of unintended spread are more firmly established. Closing and takeaways - The session closes with emphasis on careful evaluation of replicon vaccines, awareness that viral genetics can behave differently in humans than in theory, and a call for continued discussion, independent verification, and transparent communication as the technology develops. - Throughout, speakers acknowledge the complexity of immune responses to vaccines, the potential for unexpected adverse events, and the importance of safeguarding public health while advancing vaccine science.

Alarming data from the DMED database post-vaccine rollout in 2021 shows significant increases in various health issues. Myocarditis cases rose by 200%, while cancers increased by 300% to 900%. Infertility rates for both genders surged by 500%, and miscarriages rose by 300%. Neurological disorders saw a 1000% increase, with demyelinating disorders up by 500%, multiple sclerosis by 600%, and Guillain-Barré syndrome by 500%. Additionally, HIV cases increased by 500%, and pulmonary embolisms rose by 400%. These findings highlight serious health concerns linked to the vaccine.

The speaker claims injections result in blood clots, stroke, heart attack, and lost limbs, and questions why the government hasn't ordered D-dimer tests for vaccinated individuals to assess blood clot risk. Two cardiology studies allegedly found over 80% of vaccinated patients had high D-dimer levels, indicating microemboli. Microemboli in the brain, heart, or kidneys can cause organ failure and increase susceptibility to disease, potentially leading to strokes. The speaker reports seeing more cases of thrombosis of the superior sagittal sinus and transverse sinus in the brain, particularly in young people. They attribute this to microemboli and embolism caused by the spike protein from the vaccine and a nanolipid carrier entering the blood vessel wall, which they claim has been proven.